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Background: Clinical information on 24-h spirometric efficacy of combining tiotropium and sal-
meterol compared to single-agent therapy is lacking in patients with COPD.
Methods: A randomized, double-blind, four-way crossover study of 6-week treatment periods
comparing combination therapy of tiotropium 18 mg plus qd or bid salmeterol 50 mg versus
single-agent therapy. Serial 24-h spirometry (FEV1, FVC), effects on dyspnea (TDI focal score)
and rescue salbutamol use were evaluated in 95 patients.
Results: Tiotropium plus qd salmeterol was superior to tiotropium or salmeterol alone in
average FEV1 (0e24 h) by 72 mL and 97 mL (p< 0.0001), respectively. Compared to this qd
regimen, combination therapy including bid salmeterol provided comparable daytime
(0e12 h: 12 mL, pZ 0.38) bronchodilator effects, but significantly more bronchodilation
during the night-time (12e24 h: 73 mL, p< 0.0001). Clinically relevant improvements in TDI
focal score were achieved with bronchodilator combinations including salmeterol qd or bid
(2.56 and 2.71; p< 0.005 versus components). Symptom benefit of combination therapies
was also reflected in less need for reliever medication. All treatments were well tolerated.
Conclusion: Compared to single-agent therapy, combination therapy of tiotropium plus salme-
terol in COPD provided clinically meaningful improvements in airflow obstruction and dyspnea
as well as a reduction in reliever medication.
ª 2010 Elsevier Ltd. All rights reserved.l Trials Registry; all patients were entered before implementation of the registry.
ummc.nl (J.A. van Noord).
0 Elsevier Ltd. All rights reserved.
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Inhaled bronchodilators are the mainstay in the pharma-
cological management of chronic obstructive pulmonary
disease (COPD) and are recommended for treatment of
symptoms at all stages of the disease. When maintenance
therapy is required to adequately control symptoms of
COPD, the guidelines highlight long-acting bronchodilators
as being more effective and convenient, and recommend
mono- or combination therapy of these agents in moderate-
to-severe COPD.1,2
To date treatment options with long-acting bronchodi-
lators include the once-daily anticholinergic tiotropium,
providing sustained 24-h bronchodilation, and the two b2-
adrenoceptor agonists formoterol and salmeterol, requiring
twice daily dosing over a 24-h period. Numerous controlled
trials have addressed the efficacy and safety of these
agents as mono-therapies in COPD.3e8 Clinical information
on the combination of these two types of long-acting
bronchodilator is emerging. The potential benefit of co-
administration of tiotropium and twice daily b2-adreno-
ceptor agonists has been demonstrated in terms of lung
function improvement and clinical outcomes.9e19 Most of
these studies evaluated combination therapy of tiotropium
with formoterol and to date limited data exist on combi-
nation therapy with salmeterol. Previously, we showed
that co-administration of tiotropium and formoterol is
superior to single-agent therapy throughout a 24-h dosing
interval.10,11 Spirometric improvements of tiotropium plus
salmeterol with serial FEV1 and FVC measurements over
a full 24-h observation period are not available. The
present study was designed to characterize the 24-h
bronchodilating profile of tiotropium in combination with
salmeterol, to evaluate symptom relief assessed by
a reduction in dyspnea and need for reliever medication.Methods
Patients
Patients, aged 40 years and with documented diagnosis of
COPD,20 had to have a pre-bronchodilator forced expiratoryRun-in period
Screening
assessments
Randomization
(baseline)
(2 weeks)
4-way,
(doub
gµ81muiportoiT
gµ05loretemlaS
Tiotropium 18 µg + sa
Tiotropium 18 µg + sa
- FEV1, FVC
- BDI
PEFR (m
Relieve
(daytim
Figure 1 Study design of the three-centre, randomized, doubl
Tiotropium (Spiriva) and tiotropium-matched placebo powder
(Serevent, GlaxoSmithKline) and salmeterol-matched placebo via
FVC, forced vital capacity; PEFR, peak expiratory flow rate; BDI,
washout period between each 6-week period of randomized treatmvolume in one second (FEV1) 60% predicted21 and an
FEV1/FVC 70%. All were current or ex-smokers with 10
pack-yr smoking history. Specific exclusion criteria included
diagnosis of asthma, atopy, allergic rhinitis or an elevated
blood eosinophil count (600 mm3). Also, patients with
a recent history of myocardial infarction, heart failure or
cardiac arrhythmia requiring drug therapy, known symp-
tomatic prostatic hypertrophy and narrow-angle glaucoma
were excluded. Randomization of patients who suffered
from a COPD exacerbation in the 6 weeks prior to screening
or during the run-in period was postponed till 6 weeks
following recovery from the event.
Design
The hospital medical ethics committees approved the study
protocol (study code 1184.7) and written informed consent
by the patients was obtained prior to any study-related
procedure. The study had a randomized, double-blind
(double-dummy), crossover design with four 6-week treat-
ment periods (Fig. 1): tiotropium 18 mg qd via HandiHaler,
salmeterol 50 mg bid via metered-dose inhaler (MDI), tio-
tropium qd plus salmeterol qd or bid. The time interval
between inhalation of the morning and evening medication
was w12 h. Patients completed a 2-week run-in period
following screening to ensure clinical stability; this period
was also used for training of appropriate recording of daily
use of salbutamol and twice-daily peak expiratory flow rate
(PEFR). All inhaled short-acting bronchodilators (8 h) and
long-acting b2-agonists (48 h) were withdrawn at randomi-
zation (identical washout periods before screening visit);
tiotropium and theophylline preparations were not allowed
for 4 weeks prior to screening. Patients continued to use
inhaled steroids and oral steroids up to the equivalent of
daily 10 mg prednisone. Eligible patients were provided
open-label salbutamol for use of acute symptom relief.
Assessments
Following the qualifying pre-bronchodilator spirometric
test (FEV1 and FVC), severity of COPD was assessed 45 min
following inhalation of 4 puffs of salbutamol 100 mg.1 After
completion of the run-in period study baseline FEV1 and 6-week crossover*
le-blind treatment)
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e-blind, crossover study with four 6-week treatment periods.
capsule via HandiHaler (Boehringer Ingelheim); Salmeterol
metered-dose inhaler. FEV1, forced expiratory volume in 1 s;
Baseline Dyspnea Index; TDI, Transitional Dyspnea Index. *No
ent.
Combining tiotropium and salmeterol in COPD 997FVC were determined before inhalation of the first dose of
study medication. Serial spirometry was conducted at the
end of each treatment period including readings 10 min
prior to and ½, 1, 2, 3, 4, 6, 8, 10 and 12 h after inhalation
of the morning dose, and continued at ½, 1, 2, 7, 10, 11 and
12 h after inhalation of the evening dose of study medica-
tion. Testing started between 08:00 and 10:00 h with 30 min
maximum difference between the start at the randomiza-
tion visit and the tests on each 24-h pulmonary function
test-day. Measurements were performed according to
American Thoracic Society (ATS) criteria22; the highest
values of FEV1 and FVC from three technically adequate
measurements were retained.
Dyspnea was evaluated using the Baseline Dyspnea Index
(BDI) and the Transition Dyspnea Index (TDI).23 The BDI
(at randomization visit) and TDI (at the end of each 6-week
period) were administered before any other study-related
assessments were performed. Patients completed a daily
diary card recording morning and evening peak expiratory
flow rate (PEFR) always before inhalation of study medi-
cation. Use of rescue salbutamol was recorded separately
for daytime and night-time.
Safety assessments included a medical examination,
laboratory testing and a 12-lead ECG recording on entry and
upon completion of the study. At each visit clinical status
and adverse events were recorded; at the 24-h pulmonary
function test-days vital signs were recorded for the first six
hours after the morning dose.Randomly assigned to four   
6-week treatment periods 
n = 97 (all included in safety 
analysis)
Efficacy analysis 
n = 95 
(two excluded due to 
discontinuation in first  
3 weeks of first treatment) 
Discontinued study after 
randomization 
n = 8 
- adverse events n = 7 
- personal reasons n = 1 
Assessed for eligibility 
n = 103 
Figure 2 Flow diagram of the three-centre, randomized,
double-blind (double-dummy), crossover study with four
6-week treatment periods. The diagram presents information
on the number of patients screened for eligibility, randomized
to treatment, included in the efficacy analysis and the number
discontinued in the study.Statistical analysis
Primary efficacy endpointwas theaverage FEV1 over the 24-h
observation period (0e24 h). This was calculated as the area
under the curve from zero time (i.e. the pre-dose FEV1) to
24 h using the trapezoidal rule divided by the corresponding
duration (i.e. 24 h). Secondary spirometry-based endpoints
were trough, peak, average FEV1 over the first 12 h (0e12 h)
and the second 12 h (12e24 h), and FEV1 values at individual
time points. The average FEV1 (0e12 h) and FEV1 (12e24 h)
were calculated similar to FEV1 (0e24 h). Troughwas defined
as the pre-dose value measured at the beginning of the
observation period. Peak FEV1 was the highest reading
observed within 3 h after inhalation of the morning dose of
study medication. Trough, peak and average responses were
defined as the change from the study baseline FEV1, i.e. the
FEV1 determined at the randomization visit before inhalation
of the first dose of study medication. Analogous definitions
were used for FVC-based parameters. The effect on dyspnea
was evaluated using the TDI focal score; a difference of 1
unit was considered clinically meaningful. Morning and
evening PEFR, and ‘as-needed’ salbutamol (daytime and
night-time) were the diary-based endpoints. Data collected
in the first 3 weeks of each period were discarded in order to
eliminate possible carry-over effects24,25 and themeans over
remaining days of each period calculated.
The planned sample size was 80 completed patients.
Assuming a standard deviation of 135 mL for paired differ-
ences,10 this sample size provides a power of 95% to detect
a difference of 55 mL in average FEV1 (0e24 h) (type I error
rate: 0.05), resulting in an overall power for both comparisons
(combination once-daily versus single-agent therapy) of 90%.For all endpoints, adjusted means for the treatments
were calculated using a fixed-effects analysis of variance
model with terms for centre, patients within centre,
treatment and period. Patients with on-treatment data
were included in the analysis (safety: 97, diary and
spirometric endpoints: 93 and 95, respectively). Sensi-
tivity analysis did neither reveal a period effect nor
a treatment by centre interaction. For the primary
endpoint, treatment means were compared in a pre-
specified order to control type I error rate (fixed
sequence testing). For the other endpoints, no adjust-
ments for multiple comparisons were utilized. Statistical
significance was considered at p< 0.05. Missing spirom-
etry values were imputed using other values recorded for
the patient on that test-day. Data were also analyzed
based on patients who completed all 24-h pulmonary
function tests. This sensitivity analysis showed consistent
results.
Results
Ninety-seven out of 103 screened patients were random-
ized; 8 of them prematurely discontinued the trial (Fig. 2).
All treated patients were included in the safety analysis.
For two patients no efficacy data were available as they
discontinued the trial in the first three weeks of the first
treatment period. Therefore, 95 patients were included in
the efficacy analysis; Table 1 provides demographics and
baseline characteristics.
Table 1 Demographics and baseline disease characteris-
tics of patients included in the efficacy population.a
Variable Datab
No. of patients 95
Age, yr 64 9
Males/females 76/19
Smoking status
Current smokers, n (%) 25 (26)
Ex-smokers, n (%) 70 (74)
Smoking history (pack-years) 36 17
Prebronchodilator FEV1 (L) 1.09 0.34
Prebronchodilator FEV1% predicted 39 10
Postbronchodilator FEV1 (L) 1.28 0.39
Postbronchodilator FEV1% predicted 45 11
FEV1 reversibility
c
L 0.19 0.14
% baseline 18 13
% predicted 7 5
COPD severity according to GOLD
Moderate, n (%) 31 (33)
Severe, n (%) 57 (60)
Very severe, n (%) 7 (7)
Prebronchodilator FVC (L) 2.86 0.76
Prebronchodilator FEV1/FVC % 39 9
Postbronchodilator FVC (L) 3.22 0.82
Postbronchodilator FEV1/FVC % 40 10
Prestudy respiratory medication used
Inhaled anticholinergics 75 (79)
Inhaled b2-adrenergics 93 (98)
Inhaled steroid 81 (85)
Oral steroid 5 (5)
FEV1, forced expiratory volume in one second; FVC, forced vital
capacity; COPD, chronic obstructive pulmonary disease; GOLD,
Global Initiative for Chronic Obstructive Lung Disease.1
a For 2 of the 97 randomized patients no efficacy data avail-
able as they discontinued in the first 3 weeks of the first 6-week
period of randomized treatment.
b Values are presented as mean SD or No. (%) unless otherwise
stated.
c Response 45 min following four puffs of 100 mg of salbutamol
(Ventolin metered-dose inhaler, GlaxoSmithKline).
d Patients could have received more than one of these
medications.
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Figure 3 Mean) FEV1 before (trough) and during 24 h after
the inhalation of tiotropium q.d. (morning) (:), salmeterol
b.i.d. (morning and evening) (B), tiotropium q.d. plus sal-
meterol q.d. (both in the morning) (-), and tiotropium q.d.
(morning) plus salmeterol b.i.d. (morning and evening) (6) at
the end of 6-week treatment periods. The baseline mean FEV1
at the randomization visit is 1.116 L. *Adjusted for centre,
patient within centre and period.
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The 24-h FEV1 timeeresponse curves are shown in Fig. 3;
the endpoints derived from these curves are presented in
Table 2.
Combination treatment with tiotropium plus once-daily
salmeterol provided significantly greater bronchodilation
compared with the individual components as measured by
the average FEV1 (0e24 h). During the daytime (0e12 h) the
additional improvement in FEV1 versus salmeterol ranged
from 0.128 L to 0.148 L (p< 0.0001), whereas improvements
compared with tiotropium ranged from 0.069 L to 0.113 L
(p< 0.0001). Also during the night-time (12e24 h) this
combination regimen performed significantly (p< 0.001)better compared with each of the components; its sustained
bronchodilator effect was also reflected in a significantly
higher trough value. In terms of average FEV1 (0e24 h),
co-administration of tiotropium plus twice daily salmeterol
was superior (p< 0.0011) to the once-daily combination as
a result of an additional increase in FEV1 after the evening
salmeterol dose. During the daytime (0e12 h) no difference
was found,whereas during the night-time (12e24 h) allmean
FEV1 values observed at all time points for combination
therapy including salmeterol bid were significantly higher
compared with once-daily combination therapy, resulting in
a superior average FEV1 (p< 0.0001).
Treatment with tiotropium resulted in significantly
(p< 0.05) greater bronchodilation comparedwith salmeterol
in terms of average FEV1 (0e24 h), mainly due to the superior
daytime (0e12 h) spirometric efficacy of tiotropium. In
addition toahigherpeakFEV1 (p< 0.02), tiotropiumprovided
a significantly greater improvement from 6 to 12 h in the
range of 0.054 L to 0.075 L (p< 0.002). During the night-time
no difference in average FEV1 (12e24 h) was observed
between tiotropium and salmeterol.
The 24-h FVC profiles are depicted in Fig. 4 and the
derived endpoints are shown in Table 2. The results for FVC
paralleled the results found for FEV1. Both combination
therapies provided significantly higher FVC values at all
time points during the 24-h observation period compared to
each of the single agents, resulting in a significantly better
performance of combination therapy in all FVC-derived
endpoints. Also for single-agent therapy, the pattern of
improvement in FVC was similar to that in FEV1. Tiotropium
was superior to salmeterol in average FVC (0e12 h, 0e24 h)
and peak FVC, whereas no difference was found for average
FVC (12e24 h).
PEFR
PEFR data for the treatments were in line with FEV1 and
FVC results (Table 3). Both combination regimens provided
significantly additional improvements in morning and
Table 2 Average, peak and trough responsea in FEV1 and FVC, and the comparison between the four treatment regimens.
Variable Averageb Peak Trough
0e12 h 0e24 h 12e24 h
FEV1 response (L)
[Tþ S] 0.208 0.010 0.142 0.010 0.076 0.010 0.314 0.012 0.101 0.012
[Tþ S]þ S 0.221 0.010 0.185 0.009 0.148 0.010 0.331 0.012 0.158 0.012
T 0.115 0.011 0.070 0.010 0.026 0.010 0.214 0.012 0.055 0.012
Sþ S 0.068 0.011 0.045 0.010 0.021 0.010 0.173 0.012 0.033 0.013
[Tþ S] versus T,
p-value
0.093 (0.065e0.122),
<0.0001
0.072 (0.046e0.097),
<0.0001
0.050 (0.023e0.077),
0.0003
0.100 (0.067e0.133),
<0.0001
0.047 (0.013e0.080),
0.0061
[Tþ S] versus Sþ S,
p-value
0.140 (0.112e0.169),
<0.0001
0.097 (0.072e0.123),
<0.0001
0.054 (0.027, 0.081),
<0.0001
0.141 (0.108e0.174),
<0.0001
0.069 (0.036e0.102),
<0.0001
[Tþ S]þ S versus T,
p-value
0.106 (0.078e0.134),
<0.0001
0.114 (0.089e0.140),
<0.0001
0.122 (0.096e0.149),
<0.0001
0.117 (0.085e0.150),
<0.0001
0.103 (0.070e0.137),
<0.0001
[Tþ S]þ
S versus Sþ S,
p-value
0.153 (0.125e0.181),
<0.0001
0.140 (0.114e0.165),
<0.0001
0.127 (0.100e0.154),
<0.0001
0.158 (0.125e0.191),
<0.0001
0.125 (0.092e0.158),
<0.0001
[Tþ S]þ
S versus [Tþ S],
p-value
0.012 (0.016 to 0.040),
0.38
0.043 (0.017e0.068),
0.0011
0.073 (0.046e0.100),
<0.0001
0.017 (0.015 to 0.050),
0.29
0.057 (0.024e0.090),
0.0009
T versus Sþ S,
p-value
0.047 (0.019e0.075),
0.0011
0.026 (0.000e0.051),
0.0495
0.004 (0.023 to 0.031),
0.75
0.040 (0.007e0.074),
0.0166
0.022 (0.011 to 0.055),
0.20
FVC response (L)
[Tþ S] 0.357 0.017 0.251 0.016 0.144 0.019 0.535 0.021 0.198 0.025
[Tþ S]þ S 0.353 0.017 0.292 0.016 0.230 0.019 0.553 0.020 0.252 0.024
T 0.200 0.017 0.114 0.016 0.028 0.020 0.401 0.021 0.081 0.025
Sþ S 0.096 0.017 0.046 0.016 0.005 0.020 0.305 0.021 0.026 0.025
[Tþ S] versus T,
p-value
0.158 (0.112e0.203),
<0.0001
0.137 (0.093e0.181),
<0.0001
0.116 (0.064e0.169),
<0.0001
0.134 (0.079e0.190),
<0.0001
0.117 (0.051e0.184),
0.0006
[Tþ S] versus Sþ S,
p-value
0.261 (0.216e0.306),
<0.0001
0.205 (0.162e0.249),
<0.0001
0.149 (0.097e0.201),
<0.0001
0.230 (0.174e0.285),
<0.0001
0.172 (0.106e0.239),
<0.0001
[Tþ S]þ S versus T,
p-value
0.153 (0.108e0.198),
<0.0001
0.178 (0.134e0.221),
<0.0001
0.202 (0.150e0.255),
<0.0001
0.153 (0.098e0.208),
<0.0001
0.171 (0.105e0.238),
<0.0001
[Tþ S]þ
S versus Sþ S,
p-value
0.257 (0.211e0.302),
<0.0001
0.246 (0.202e0.289),
<0.0001
0.235 (0.183e0.287),
<0.0001
0.248 (0.193e0.304),
<0.0001
0.226 (0.160e0.293),
<0.0001
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1000 J.A. van Noord et al.evening PEFRs compared with single-agent therapy. No
difference was found between the single agents in morning
PEFR, whereas tiotropium was superior to salmeterol in
terms of evening PEFR.
Dyspnea and use of rescue salbutamol
The mean (SE) BDI focal score was 7.0 (2.5). Both
combination regimens provided a clinically and statistically
significant (p< 0.005) improvement in mean TDI focal score
compared to each of the single agents (Table 3). The
proportion of patients who achieved a clinically meaningful
improvement in TDI focal score was greater during treat-
ment with tiotropium plus salmeterol qd (67%) or bid (72%)
than for the salmeterol (48%) or tiotropium (57%) periods.
The improvement in TDI focal score is associated with
significantly less need of salbutamol (Fig. 5). When on
combination therapy patients used significantly (p< 0.001)
less salbutamol over a 24-h period compared with single-
agent therapy, which reflected mainly the reduced use
during the daytime (Table 3). No difference was observed
between the combination regimens as well as between the
two single long-acting agents.
Safety
Seven patients discontinued the study due to an adverse
event: two patients when on combination therapy (tio-
tropium plus salmeterol qd: hospitalization due to lung
cancer; tiotropium plus salmeterol bid: increase of dysp-
nea), one patient in the tiotropium period (hepatic cysts)
and four patients when on salmeterol. Of these four
patients, one was withdrawn due to drug sensitivity
(considered related to study medication), another patient
due to atrial fibrillation requiring hospitalization, and two
patients hospitalized due to a COPD exacerbation; in
addition to the COPD exacerbation in one patient a deteri-
oration of dementia was noted, the patient died during
hospitalization (death unexplained).
Although the incidence of adverse events was generally
balanced between the treatment periods (Table 4), during
combination therapy a lower incidence was noted for COPD
exacerbations and complaints of dyspnea. Measurements of
blood pressure and pulse rate did not reveal any difference
between combination and single-agent therapies. The post-
study ECG recordings and laboratory safety screen did not
indicate any study drug-related changes.
Discussion
This is the first study evaluating benefit of combination
therapy of tiotropium and salmeterol in patients with
COPD compared with the individual components in phar-
macodynamic steady state. Both combination regimens
were superior to single-agent therapy in terms of 24-h
lung function improvement, TDI focal score and use of
reliever medication. The superior bronchodilator effects
were not only restricted to the relevant period of daily
activities (0e12 h), but were also observed during the
night-time (12e24 h) and did not increase the incidence of
side effects.
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Figure 4 Mean) FVC before (trough) and during 24 h after
the inhalation of tiotropium q.d. (morning) (:), salmeterol
b.i.d. (morning and evening) (B), tiotropium q.d. plus sal-
meterol q.d. (both in the morning) (-), and tiotropium q.d.
(morning) plus salmeterol b.i.d. (morning and evening) (6) at
the end of 6-week treatment periods. The baseline mean FVC
at the randomization visit is 2.934 L. *Adjusted for centre,
patient within centre and period.
Combining tiotropium and salmeterol in COPD 1001During daytime substantially higher peak and average
FEV1 and FVC responses were observed for the once-daily
combination regimen compared to either component. This
combination including only one dose of salmeterol provided
significantly higher trough FEV1 and FVC values, indicating
sustained 24-h bronchodilator effects, which is supported
by significantly higher average FEV1 and FVC values during
the nigh-time (12e24 h). The spirometric endpoints trough
and average night-time response demonstrate that the
individual components, tiotropium (full-daily dose) and
salmeterol (half-daily dose), both contributed to the over-
all 24-h bronchodilator effect of the once-daily combina-
tion. As expected, due to the evening salmeterol dose, the
combination regimen including twice daily salmeterol was
the most effective of all treatments in particular during the
night-time period (12e24 h); no additional spirometric
benefit was found during daytime (0e12 h).
One of the management goals of maintenance bron-
chodilator therapy is to achieve improvement in dyspnea onTable 3 Three-weekly peak flow (morning and evening) and n
Dyspnea Index (TDI) focal score results at the end of 6-week trea
Tiotropium Salmete
Peak flow (L/min)
Morning 263 1.9 260 1
Evening 278 1.8*** 268 1
Rescue salbutamol use
Daytime (0e12 h) 1.88 0.11 1.81 0
Night-time (12e24 h) 0.39 0.04 0.37 0
TDI focal score 1.18 0.28 0.97 0
*p< 0.005 versus tiotropium and versus salmeterol; **p< 0.05 versu
tiotropium plus salmeterol qd.
Data are presented as mean SE.
Treatment responses are adjusted for centre, patient within centre aactivities of daily living. In this respect, both combination
regimens provided significantly (p< 0.001) and clinically
(1 unit change in focal score26) greater relief of dyspnea
compared with either agent alone. The magnitude of the
improvement in dyspnea with tiotropium combined with
salmeterol amounted to approximately a mean TDI focal
score of 2.64, substantially higher than with tiotropium or
salmeterol alone where improvements in mean TDI focal
score of 1.18 and 0.97, respectively, were observed. The
improvements of >2 units observed with tiotropium plus
salmeterol are in line with recent combination studies
including tiotropium.14,15,18 Generally, this standardized
instrument to measure breathlessness related to activities
of daily living is used in trials employing a parallel design,
however, also in the present crossover trial the TDI instru-
ment appeared to be sensitive enough to discriminate
patients’ responsiveness in perceived breathlessness
between single-agent and combination therapy. The
marked bronchodilator-mediated symptomatic benefit of
combination therapy is associated with a decreased need of
salbutamol for acute symptom relief. Rescue medication
use was approximately 5e6 times higher during the period
when patients tend to be active (i.e. daytime) compared to
the period when they are in rest (i.e. night-time) as
observed previously as well.10 Remarkably, in the tio-
tropium plus salmeterol bid period, the additional need for
salbutamol was comparable to the period when patients
inhaled salmeterol only in the morning on top of tio-
tropium. This indicates that the omission of the evening
salmeterol dose, which can be seen as equivalent to four
puffs of salbutamol over a 12 h period,27 did not result in
more symptoms requiring rescue salbutamol use.
As indicated above, published data on pulmonary effects
of combination therapy with tiotropium and salmeterol is
limited. Interestingly, the present results of once-daily
combination in pharmacodynamic steady state can be
compared with a single dose study conducted by Cazzola
et al.,9 in which the functional impact of adding salmeterol
to tiotropium was also examined over 24 h. Following acute
dosing, combination therapy elicited a significantly faster
onset of action and showed a trend for a greater maximum
bronchodilation than the single components alone, while inumber of puffs per day of rescue salbutamol, and Transition
tment periods.
rol bid Tiotropium plus
salmeterol qd
Tiotropium plus
salmeterol bid
.9 272 1.9* 278 1.9*,****
.8 289 1.8* 288 1.8*
.12 1.25 0.11* 1.28 0.11*
.04 0.27 0.04** 0.19 0.04*
.28 2.56 0.27* 2.71 0.27*
s tiotropium; ***p< 0.0001 versus salmeterol; ****p< 0.05 versus
nd period.
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Figure 5 Improvement of Transition Dyspnea Index focal score (left panel) is associated with less need for rescue salbutamol
(right panel). Baseline Dyspnea Index (BDI) is 7.00. *p< 0.001 compared with either single agent alone. MCID: minimal clinically
important difference (i.e. improvement of 1 unit).
1002 J.A. van Noord et al.terms of duration of effect (i.e. 12 and 24 h post-dosing)
combination therapy was only statistically significant
when compared to salmeterol. The present study shows
that definitive conclusions on the pulmonary effects of
single long-acting bronchodilators in relation to their
combination can only be drawn following maintenance
therapy, i.e. when pharmacodynamic steady state is ach-
ieved. In line with Cazzola et al., during the first hours
post-dosing the once-daily combination regimen provided
superior bronchodilation compared to either component
and the onset of action, as judged from the FEV1
improvements at 30 min after inhalation, was significantly
faster (p< 0.0001, both) as well. However, in pharmaco-
dynamic steady state also during the night-time hours
[average FEV1 (12e24 h)] the improvements in spirometric
parameters with the once-daily combination were sus-
tained, with significantly higher trough FEV1 and FVC
values. The additive effects in pre-bronchodilator (trough)
FEV1 observed with tiotropium plus twice daily salmeterol
in the present study differ from the findings in the 1-year
intervention study by Aaron et al.,12 who found that
tiotropium plus twice daily salmeterol did not statistically
improve the pre-bronchodilator FEV1 compared to treat-
ment with tiotropium alone. However, in particular whenTable 4 Adverse events.a
Event Tiotropium Salm
Total treated n 93 93
Total with any adverse event 47 (50.5) 47 (5
Influenza 0 (0.0) 1 (1
Nasopharyngitis 14 (15.1) 12 (1
Headache 1 (1.1) 1 (1
COPD exacerbated 10 (10.8) 15 (1
Dyspnea exacerbated 12 (12.9) 13 (1
Data are presented as n (%), unless otherwise stated.
COPD, chronic obstructive pulmonary disease.
a Occurring in 3% of the patients.trough values are assessed after treatment with long-acting
drugs like tiotropium28,29 or combined tiotropium plus
LABA,10,11 it is preferred to standardize the timing (and
time window) of the morning pre-bronchodilator lung
function measurement, in view of circadian variations, with
a substantial rise in the early morning FEV1. Since the
timing of the pulmonary assessments was not given, and
more than 40% of patients discontinued therapy prema-
turely, it is difficult to compare the results from both
studies. In addition, the reversible component of the
airflow obstruction in the present study population was
higher (0.19 L) compared to the population in the 1-year
intervention study (0.07 L). Improvement of airflow
obstruction (FEV1) and hyperventilation-evoked hyperin-
flation (IC) has been documented by Eguchi et al.13
Compared to tiotropium alone, combination therapy with
salmeterol provided greater improvements in FEV1, while
no additional benefit was found for IC. Since this trial was
designed as an open-label, non-randomized study (treat-
ment with tiotropium alone followed by combination
therapy), this study is most probably suffering from meth-
odological issues, as indicated by the authors. Employing
a double-blind, cross-over design we have evaluated
dynamic hyperinflation (IC) induced by an increase ineterol bid Tiotropium plus
salmeterol qd
Tiotropium plus
salmeterol bid
92 92
0.5) 40 (43.5) 42 (45.7)
.1) 2 (2.2) 4 (4.3)
2.9) 13 (14.1) 15 (16.3)
.1) 0 (0.0) 3 (3.3)
6.1) 5 (5.4) 7 (7.6)
4.0) 1 (1.1) 2 (2.2)
Combining tiotropium and salmeterol in COPD 1003breathing frequency during combination treatment with
tiotropium plus salmeterol as well as during tiotropium and
salmeterol alone.30 Combination therapy resulted in the
greatest reduction in dynamic hyperinflation compared to
single-agent therapy.
To explore the benefit of combination therapy of tio-
tropium plus salmeterol it was considered mandatory to
include 24-h spirometric assessments. Therefore, the
present study provides the opportunity to compare the
improvements in FEV1 and FVC of the single-agent therapies
in their approved posology over a 24-h period. The superior
daytime bronchodilator efficacy of tiotropium over salme-
terol is consistent with previous findings31 and is explained
by the longer duration of action of tiotropium. During
the night-time period no difference was found in average
FEV1 and FVC response between the two long-acting
bronchodilators.
Previously, we reported superior improvement in airflow
limitation with combination treatment of tiotropium plus
formoterol.10 Interestingly, the results also suggested
a more than additive effect, i.e. the combined effect was
greater or longer lasting than predicted from addition of
components. Also in the present study it appears that the
morning dose of salmeterol, in addition to tiotropium, still
provides added efficacy after 12 h, whereas salmeterol
alone had returned to the test-day (morning) baseline 8 h
after the morning dose. This finding could be explained by
the fact that acetylcholine-stimulated muscarinic M3
receptors, generating inositol-1,4,5-trisphosphate and
diacylglycerol (DAG) as second messengers, may have
a major influence on b2-adrenoceptor function. This is due
to DAG-induced activation of protein kinase C which may
phosphorylate the b2-adrenoceptor and the Gs-protein,
causing b2-receptor uncoupling and desensitisation,
32,33
and phosphorylate and activate b-adrenoceptor kinases
[bARKs; members of the G-protein receptor kinase (GRK)
family], amplifying b-agonist-induced desensitisation.34
Hence, M3-receptor blockade by tiotropium may not only
antagonise acetylcholine-mediated airway constriction,
but may also amplify and prolong salmeterol-induced
b2-receptor activation after receptor occupancies have
reached their steady state, and the in time diminishing
b2-adrenoceptor activation by salmeterol is being increas-
ingly potentiated by (slower dissociating) tiotropium.
Confirmation of this hypothesis based on the current
findings is hampered by the lack of a placebo control
period. FEV1 values have been shown to drop below the
pre-treatment morning baseline due to the circadian
variation in airflow limitation.11,28 This means that without
a correction for the placebo response, the calculated sum
of the average FEV1 responses for the individual compo-
nents will be underestimated when compared to the
response observed for the free combination regimen.
Therefore, an additional study including a placebo control
period is required to establish the magnitude of the addi-
tive effect during a 24-h period.
In summary, the present study confirms and supports the
recommendations of the guidelines on pharmacotherapy of
COPD1,2 to combine two long-acting bronchodilators with
different pharmacological mechanisms in patients who
require both classes of drugs for optimal control of their
disease. Optimal bronchodilation, relief of breathlessnessand reduced use of reliever medication were achieved with
combination therapy of tiotropium and salmeterol.
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